Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

141 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia.
Paiva B, Vidriales MB, Sempere A, Tarín F, Colado E, Benavente C, Cedena MT, Sánchez J, Caballero-Velazquez T, Cordón L, Garces JJ, Simoes C, Martínez-Cuadrón D, Bernal T, Botella C, Grille S, Serrano J, Rodríguez-Medina C, Algarra L, Alonso-Domínguez JM, Amigo ML, Barrios M, García-Boyero R, Colorado M, Pérez-Oteyza J, Pérez-Encinas M, Costilla-Barriga L, Sayas MJ, Pérez O, González-Díaz M, Pérez-Simón JA, Martínez-López J, Sossa C, Orfao A, San Miguel JF, Sanz MÁ, Montesinos P; PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group. Paiva B, et al. Leukemia. 2021 Aug;35(8):2358-2370. doi: 10.1038/s41375-021-01126-3. Epub 2021 Feb 1. Leukemia. 2021. PMID: 33526859
Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens.
Montesinos P, Rayón C, Vellenga E, Brunet S, González J, González M, Holowiecka A, Esteve J, Bergua J, González JD, Rivas C, Tormo M, Rubio V, Bueno J, Manso F, Milone G, de la Serna J, Pérez I, Pérez-Encinas M, Krsnik I, Ribera JM, Escoda L, Lowenberg B, Sanz MA; PETHEMA; HOVON Groups. Montesinos P, et al. Blood. 2011 Feb 10;117(6):1799-805. doi: 10.1182/blood-2010-04-277434. Epub 2010 Dec 8. Blood. 2011. PMID: 21148082 Free article. Clinical Trial.
Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction.
Ramos F, Thépot S, Pleyer L, Maurillo L, Itzykson R, Bargay J, Stauder R, Venditti A, Seegers V, Martínez-Robles V, Burgstaller S, Récher C, Debén G, Gaidano G, Gardin C, Musto P, Greil R, Sánchez-Guijo F, Fenaux P; European ALMA Investigators. Ramos F, et al. Leuk Res. 2015 Mar;39(3):296-306. doi: 10.1016/j.leukres.2014.12.013. Epub 2014 Dec 31. Leuk Res. 2015. PMID: 25601157
All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies.
Sanz MA, Montesinos P, Kim HT, Ruiz-Argüelles GJ, Undurraga MS, Uriarte MR, Martínez L, Jacomo RH, Gutiérrez-Aguirre H, Melo RA, Bittencourt R, Pasquini R, Pagnano K, Fagundes EM, Vellenga E, Holowiecka A, González-Huerta AJ, Fernández P, De la Serna J, Brunet S, De Lisa E, González-Campos J, Ribera JM, Krsnik I, Ganser A, Berliner N, Ribeiro RC, Lo-Coco F, Löwenberg B, Rego EM; IC-APL and PETHEMA and HOVON Groups. Sanz MA, et al. Ann Hematol. 2015 Aug;94(8):1347-56. doi: 10.1007/s00277-015-2393-0. Epub 2015 May 15. Ann Hematol. 2015. PMID: 25975975 Clinical Trial.
A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia.
Bergua JM, Montesinos P, Martinez-Cuadrón D, Fernández-Abellán P, Serrano J, Sayas MJ, Prieto-Fernandez J, García R, García-Huerta AJ, Barrios M, Benavente C, Pérez-Encinas M, Simiele A, Rodríguez-Macias G, Herrera-Puente P, Rodríguez-Veiga R, Martínez-Sánchez MP, Amador-Barciela ML, Riaza-Grau R, Sanz MA; PETHEMA group. Bergua JM, et al. Br J Haematol. 2016 Sep;174(5):700-10. doi: 10.1111/bjh.14107. Epub 2016 Apr 26. Br J Haematol. 2016. PMID: 27118319 Free article.
Prognostic risk models for transplant decision-making in myelofibrosis.
Hernández-Boluda JC, Pereira A, Correa JG, Alvarez-Larrán A, Ferrer-Marín F, Raya JM, Martínez-López J, Velez P, Pérez-Encinas M, Estrada N, García-Gutiérrez V, Fox ML, Payer A, Kerguelen A, Cuevas B, Durán MA, Ramírez MJ, Gómez-Casares MT, Mata-Vázquez MI, Mora E, Gómez M, Cervantes F. Hernández-Boluda JC, et al. Ann Hematol. 2018 May;97(5):813-820. doi: 10.1007/s00277-018-3240-x. Epub 2018 Jan 25. Ann Hematol. 2018. PMID: 29396714
An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens.
Sobas M, Montesinos P, Boluda B, Bernal T, Vellenga E, Nomdedeu J, González-Campos J, Chillón M, Holowiecka A, Esteve J, Bergua J, González-Sanmiguel JD, Gil-Cortes C, Tormo M, Salamero O, Manso F, Fernández I, de la Serna J, Moreno MJ, Pérez-Encinas M, Krsnik I, Ribera JM, Escoda L, Lowenberg B, Sanz MA; PETHEMA, HOVON, PALG, and GATLA cooperative groups. Sobas M, et al. Leuk Lymphoma. 2019 Apr;60(4):1030-1035. doi: 10.1080/10428194.2018.1516875. Epub 2018 Oct 15. Leuk Lymphoma. 2019. PMID: 30322324
Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy.
Labrador J, Luño E, Vellenga E, Brunet S, González-Campos J, Chillón MC, Holowiecka A, Esteve J, Bergua J, González-Sanmiguel JD, Gil C, Tormo M, Salamero O, Manso F, Fernández I, de laSerna J, Moreno MJ, Pérez-Encinas M, Krsnik I, Ribera JM, Cervera J, Calasanz MJ, Boluda B, Sobas M, Lowenberg B, Sanz MA, Montesinos P. Labrador J, et al. Leuk Lymphoma. 2019 May;60(5):1146-1155. doi: 10.1080/10428194.2018.1522438. Epub 2018 Dec 11. Leuk Lymphoma. 2019. PMID: 30526152
Real life outcomes of patients aged ≥75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry.
Salamero O, Martínez-Cuadrón D, Sobas M, Benavente C, Vives S, De la Serna J, Pérez-Encinas M, Escoda L, Gil C, Brunet S, Ramos F, Esteve J, Amigo M, Krsnik I, Manso F, Arias J, González-Campos J, Serrano J, Oleksiuk J, Barrios M, García-Boyero R, Novo A, Sanz MA, Montesinos P; PETHEMA and PALG Groups. Salamero O, et al. Leuk Lymphoma. 2019 Nov;60(11):2720-2732. doi: 10.1080/10428194.2019.1607327. Epub 2019 May 9. Leuk Lymphoma. 2019. PMID: 31068052
Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols.
Sobas M, Rodriguez-Veiga R, Vellenga E, Paluszewska M, De la Serna J, García-Álvarez F, Gil C, Brunet S, Bergua J, González-Campos J, Ribera JM, Tormo M, González M, Fernández I, Benavente C, González-Sanmiguel JD, Esteve J, Pérez-Encinas M, Salamero O, Manso F, Lowenberg B, Sanz MA, Montesinos P; PETHEMA, HOVON, PALG, GATLA cooperative groups. Sobas M, et al. Eur J Haematol. 2020 Mar;104(3):162-169. doi: 10.1111/ejh.13346. Epub 2020 Jan 22. Eur J Haematol. 2020. PMID: 31724208
141 results